Finance & Capital Markets

31. Episode 2: The Business Of Biotech: Allan Shaw 8/13/2020

    There are few better suited to advise the leaders of new and emerging biopharma companies on the building blocks of a biotech startup than Allan Shaw. That's why we chose Shaw to help us kick off our Business of Biotech podcast series with an overview of the episodes to come. In addition to his work on the financial front lines of several biotechs, Shaw holds multiple board of director roles with startup biopharma firms, and he advises dozens more in his role as special adviser. On this episode, we'll preview the series and absorb Shaw's to-the-point, practical advice on winning finances, building a pitch, assembling a biotech all-star team, leaving the incubator, navigating early regulatory considerations, and a whole lot more. The Business Of Biotech is produced by BioProcess Online and brought to you with the support of Cytiva.

32. Venture Philanthropy For Type 1 Diabetes With T1D Fund's Katie Ellias 1/19/2022

    The JDRF's T1D Fund is exemplary of an indication-specific advocacy group's aggressive pursuit of a cure through venture philanthropy. Put simply, unlike traditional VC firms who entertain myriad and often diverse pitches from biotech startups, the T1D fund creates financial and advisory incentives for the biotechs in its portfolio to pursue candidates and formalize programs around Type 1 Diabetes therapies.

33. Financing Biopharma Innovation With Allan Shaw 12/19/2022

    Friend and frequent guest Allan Shaw rejoins the Business of Biotech to reflect on his recent presentation on innovative biotech financing at the BioFuture event in NYC. We also dig into Bruce Booth's "Atlas Venture Year In Review," revisiting and unpacking some quoteworthy material and metrics from both sources. Allan offers up plenty of prognostication and professional insight in a preview of what's to come in 2023, complete with his signature "Allanisms" and colorful analogies. A can't-miss episode as we round the turn to a new year!

34. Building A Biotech Incubator And Accelerator With Swiss Rockets Founder And CEO Vladimir Cmiljanovic, Ph.D. 8/21/2025

    On this week's episode, ex-handballer Vladimir Cmiljanovic, Ph.D., Founder and CEO at Swiss Rockets, talks about co-discovering bimiralisib with his sister Natasa Cmiljanovic, Ph.D. (and COO at Swiss Rockets), losing his company to a hostile takeover, buying the company back, and building out Swiss Rockets as an incubator with manufacturing capabilities and shared scientific expertise.

35. Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier 11/5/2025

    On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. 

36. Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary 4/24/2026

    On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily neuroreparative peptide designed to restore function in patients with spinal cord injuries.

37. Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt 11/26/2025

    On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer.

38. Biotech Funding And IPO Temperature Check With CREATE Medicine's Allan Shaw 11/13/2025

    Allan Shaw, Chief Financial Officer and Chief Business Officer at CREATE Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market.

39. Serial Success With Triumvira's Rob Williamson 3/10/2024

    Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Learn secrets to his serial success on this week's Business of Biotech podcast.

40. Veteran Advice From The C-Suite With Citius' Leonard Mazur 10/4/2023

    Leonard Mazur has been in the business of biotech for a long, long time, and he has no intention of stopping now. He’s faced challenges won, lost, and ongoing, and he’s willing to share his experiences—from winning FDA approvals to bootstrapping his current effort at Citius Pharmaceuticals—with the transparent confidence of an industry veteran.